Navigation Links
Deltanoid Pharmaceuticals begins phase II osteoporosis study

Madison, Wis. - Deltanoid Pharmaceuticals, a privately held pharmaceutical company based in Madison, has begun a Phase 2 clinical study of 2MD, its lead osteoporosis compound.

The study is being conducted to determine whether 2MD can safely improve bone mineral density in postmenopausal women. Osteoporosis, a disease caused by the loss of norm......

Full article >>>
'"/>

Source:wistechnology.com By WTN News 03/13/07


Page: 1

Related biology technology :

1. Deltanoid presses on with drug research
2. Deltanoid named to top-15 list of biotech companies
3. The Coming of Biotech Generic Pharmaceuticals
4. DeForest biodiesel plant begins production
5. Prodesse begins clinical trials for flu virus detection
6. Closing the income gap begins with education
7. Corporate control begins with a strong board
8. Emerging game developer begins work on prototypes
9. GE begins human trials for cancer detection agent
10. Now the real work begins
11. Esker begins automated faxing and mailing service
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/23/2017)... 2017  Seattle,s upscale Capitol Hill neighborhood, with its swanky shops, ... a head lice treatment salon to set up shop. But ... and a French bistro on E Madison Ave, and CEO ... any old lice clinic, we pride ourselves on being a ... some of the stigma associated with lice. Everyone can get ...
(Date:2/23/2017)... ... February 23, 2017 , ... David Nolte, PhD ... Reception at Purdue Research Park of West Lafayette, Indiana. , The ... outstanding contributions to, and success with, commercializing discoveries from Purdue research. “This award ...
(Date:2/23/2017)... DIEGO , Feb. 23, 2017 ... research tools, announced the acquisition of GenWay Biotech ... a comprehensive service and product offering for both ... acquisition will facilitate growth and enhance capabilities for ... antibodies, and ELISA assays will nicely complement ASB,s ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... has acquired Kendall Research Systems, LLC (KRS) clinical development program. KRS ... neural interface technology for research and clinical applications. The terms of the transaction ...
Breaking Biology Technology:
(Date:2/3/2017)... 3, 2017  Texas Biomedical Research Institute announced that its ... Schlesinger as the Institute,s new President and CEO. Dr. ... 31, 2017. He is currently the Chair of the Department ... for Microbial Interface Biology at Ohio State University. ... President and CEO of Texas Biomed," said Dr. James ...
(Date:2/2/2017)... , Feb. 2, 2017  EyeLock LLC, a market ... new white paper " What You Should Know About ... of ensuring user authenticity is a growing concern. In ... of users. However, traditional authentication schemes such as username/password ... Biometric authentication offers an elegant solution to the ...
(Date:1/31/2017)... 2017  Spero Therapeutics, LLC, a biopharmaceutical company ... of bacterial infections, today announced it has acquired ... Pro Bono Bio Ltd (PBB) to bolster its ... forms of Gram-negative bacteria.   The assets acquired have ... PBB group company. "The acquisition of ...
Breaking Biology News(10 mins):